Clinical Trial: Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional




Official Title: Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer

Brief Summary: This study is designed to see whether Apatinib is effective in treating patients with advanced refractory biliary tract cancers.